Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inhibitors of p56(lck): assessing their potential as tools for manipulating T-lymphocyte activation
Autore:
Dowden, J; Ward, SG;
Indirizzi:
Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England Univ Bath Bath Avon England BA2 7AY harmacol, Bath BA2 7AY, Avon, England
Titolo Testata:
EXPERT OPINION ON THERAPEUTIC PATENTS
fascicolo: 2, volume: 11, anno: 2001,
pagine: 295 - 306
SICI:
1354-3776(200102)11:2<295:IOPATP>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTEIN-TYROSINE KINASES; CELL ANTIGEN RECEPTOR; HIGH-AFFINITY LIGANDS; SIGNAL-TRANSDUCTION; SH2 DOMAIN; LCK; DISCOVERY; COMPLEX; CD4; NMR;
Keywords:
indandiones; isothiazolones; natural products; p56(lck); pyrazolopyrimidines; pyridopyrimidines; quinazolines; SH2 domains; TCR; T-lymphocytes;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Dowden, J Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England Univ Bath Bath Avon England BA2 7AY Bath BA2 7AY, Avon, England
Citazione:
J. Dowden e S.G. Ward, "Inhibitors of p56(lck): assessing their potential as tools for manipulating T-lymphocyte activation", EXPERT OP T, 11(2), 2001, pp. 295-306

Abstract

The Src family tyrosine kinase p56(lck) is predominantly expressed in T-lymphocytes and natural killer cells and there is an absolute requirement forp56lck in T-cell development and activation. Consequently, there has been much effort in developing small molecule antagonists for p56(lck) with a view for therapeutic use in a number of T-lymphocyte-dependent diseases. A large majority of protein kinase inhibitors are directed toward the ATP binding site and gain their specificity by exploiting adjacent topographical variations. To date, the most potent and widely studied class of Lck inhibitors are the pyrazolopyrimidines, which have proven to be valuable research tools. The development of pyrido[2,3-d]pyrimidine structures offer excellent potency and selectivity from a different structural platform and together these appear to offer the most promising scaffolds for the development of future therapeutics. SH2 domain inhibition offers the potential reward of escaping the constraints of the ATP binding site but developing potent and specific inhibitors of protein-protein interactions presents a significant challenge. The results briefly discussed in this review reveal the extent of progress toward this goal.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 15:56:35